Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)

China · Delayed Price · Currency is CNY

14.72

-0.61 (-3.98%)

Jun 11, 2026, 2:55 PM CST

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
In Vitro Diagnostic Products and Solutions	220.05M	220.14M	393.38M	9.97B	-
In Vitro Diagnostic Products and Solutions Growth	-0.04%	-44.04%	-96.05%	-	-
Business Operations and Others	45.02M	129.92M	-	-	-
Business Operations and Others Growth	-65.34%	-	-	-	-
Third-Party Medical Testing	-	-	297.96M	421.72M	115.00M
Third-Party Medical Testing Growth	-	-	-29.35%	266.72%	31.24%
Agency Business	-	-	58.20M	137.17M	135.08M
Agency Business Growth	-	-	-57.57%	1.54%	100.59%
in Vitro Diagnostic Reagent	-	-	-	-	2.47B
in Vitro Diagnostic Reagent Growth	-	-	-	-	216.11%
in Vitro Diagnostic Equipment	-	-	-	-	24.93M
in Vitro Diagnostic Equipment Growth	-	-	-	-	93.53%
Emergency and Critical Care Information Solutions	-	-	-	-	39.00M
Emergency and Critical Care Information Solutions Growth	-	-	-	-	313.16%
Others	-	-	-	-	44.45M
Total	265.08M	350.06M	749.54M	10.53B	2.83B
Total Growth	-24.28%	-53.30%	-92.88%	272.12%	195.05%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Northeast China	2.16M	4.37M	62.47M	844.97M	271.16M
Northeast China Growth	-50.69%	-93.00%	-92.61%	211.61%	169.37%
North China	9.49M	13.89M	26.55M	713.21M	214.87M
North China Growth	-31.65%	-47.70%	-96.28%	231.93%	266.81%
Eastern China	17.64M	21.52M	61.98M	3.03B	462.07M
Eastern China Growth	-18.05%	-65.28%	-97.96%	556.01%	402.43%
Southern China	26.70M	79.89M	348.19M	1.76B	479.66M
Southern China Growth	-66.58%	-77.05%	-80.19%	266.36%	207.04%
Central	67.81M	104.95M	98.33M	1.49B	329.75M
Central Growth	-35.39%	6.73%	-93.39%	351.43%	36.64%
Northwestern	58.52M	84.77M	121.72M	2.08B	700.97M
Northwestern Growth	-30.96%	-30.36%	-94.15%	196.66%	237.18%
Southwest	29.78M	11.56M	19.52M	317.26M	122.28M
Southwest Growth	157.61%	-40.80%	-93.85%	159.45%	614.54%
Overseas	52.99M	29.12M	10.78M	298.25M	249.07M
Overseas Growth	82.00%	170.11%	-96.39%	19.75%	191.90%
Total	265.08M	350.06M	749.54M	10.53B	2.83B
Total Growth	-24.28%	-53.30%	-92.88%	272.12%	195.05%

Source: S&P Global Market Intelligence.